Drug Profile
KUS 121
Alternative Names: KUS-121Latest Information Update: 17 Apr 2024
Price :
$50
*
At a glance
- Originator Kyoto University
- Developer Kyoto Drug Discovery & Development; Kyoto University
- Class Eye disorder therapies
- Mechanism of Action CDC48 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Retinal artery occlusion
- Phase I/II Retinal vascular occlusion
Most Recent Events
- 03 Apr 2024 Phase-II clinical trials in Retinal Artery Occlusion (Newly-diagnosed) in USA (Intravitreous) (NCT06178055)
- 20 Dec 2023 Kyoto Drug Discovery and Development plans a phase II trial for Retinal vascular occlusion in January 2024 (Intravitreous) (NCT06178055)
- 20 Mar 2018 Kyoto Drug Discovery and Development completes phase I/II trials in Retinal vascular occlusion in Japan (UMIN000023979)